Creating new imaging and treatment methods for multiple myeloma using CD46
Development of CD46 theranostics for imaging and treatment of multiple myeloma
This study is exploring new ways to find and treat multiple myeloma by creating special agents that target a protein called CD46, which is found in high amounts in myeloma cells, to help doctors see the cancer better and fight it more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10874404 on NIH RePORTER |
What this research studies
This research focuses on developing innovative theranostic agents that target CD46, a protein found in high levels in multiple myeloma (MM) cells. The project aims to create imaging agents and therapeutic treatments that can help visualize and combat MM. Researchers will use advanced techniques to test these agents in preclinical models and conduct a pilot study with patients. The goal is to improve the detection and treatment of MM, potentially leading to better patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma who are seeking new treatment options.
Not a fit: Patients with other types of cancers or those without a diagnosis of multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective imaging and treatment options for patients with multiple myeloma.
How similar studies have performed: Other research has shown promise in using targeted therapies and imaging agents for cancer treatment, indicating that this approach could be effective.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Flavell, Robert Richard — University of California, San Francisco
- Study coordinator: Flavell, Robert Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.